61 results
8-K
EX-99.1
NKTX
Nkarta Inc
27 Jun 24
Patient screening underway in Ntrust-1, the first U.S.-based clinical trial of an engineered NK cell therapy for the treatment of lupus nephritis
6:45am
organ damage and an increased risk of death. Lupus nephritis (LN) is among the most severe manifestations of SLE. Approximately 40 percent
424B5
NKTX
Nkarta Inc
25 Mar 24
Prospectus supplement for primary offering
8:15pm
and to such director’s earlier death, resignation or removal.
Special Meetings of Stockholders. Our Certificate of Incorporation and Bylaws provide that special
8-K
EX-99.1
08x hjvse
17 Oct 23
Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis
7:06am
S-3/A
umsa12m2 890w70nwg8b
24 Apr 23
Shelf registration (amended)
5:21pm
PRE 14A
wjod9asp2tkxv9c172l
14 Apr 23
Preliminary proxy
5:00pm
8-K
EX-99.2
hw2f6ygp loos
5 Dec 22
Regulation FD Disclosure
7:39am
424B5
o9e49e0u5u3s8z
26 Apr 22
Prospectus supplement for primary offering
4:02pm
424B5
4tf7pqt0
25 Apr 22
Prospectus supplement for primary offering
4:03pm
8-K
EX-99.2
fcs tp2zt
25 Apr 22
Nkarta Announces Positive Preliminary Dose Finding Data for Two Lead Engineered Natural Killer Cell Programs
7:52am